As of July 23, 2026, the peptides with the clearest legal prescribing path are FDA-approved tesamorelin (Egrifta) and the Category 1 compounding substances sermorelin and ipamorelin. BPC-157, TB-500, KPV, and MOTs-C remain Category 2 and are not eligible for patient-specific compounding — but that picture is actively shifting: on July 23 the FDA’s advisory committee voted to recommend BPC-157 and KPV for the 503A list, against the agency’s own staff position. A recommendation is not a rule, so nothing has changed for patients yet. This page is on a 30-day re-verification cycle while FDA action is pending; the FDA’s published lists are the authoritative source.
Which peptides are legal to prescribe right now
Three have a clear path. Tesamorelin is FDA-approved as Egrifta, so it is a fully legal prescription drug; compounded versions are also prepared by licensed pharmacies. Sermorelin (a GHRH analog once FDA-approved as Geref) and ipamorelin are classified Category 1 — 503A compounding pharmacies may prepare them under a valid, patient-specific prescription while the FDA completes its review.
Which peptides are still restricted
The peptides most discussed online — BPC-157, TB-500, KPV, and MOTs-C — are Category 2 as of July 23, 2026, meaning they are not eligible for 503A patient-specific compounding while the FDA evaluates them. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed those four on July 23, 2026, with Emideltide (DSIP), Semax, and Epitalon following on July 24.
What happened at the July 23–24, 2026 meeting
The FDA’s own briefing documents proposed that none of the seven peptides be added to the 503A Bulks List, citing insufficient effectiveness and safety evidence and incomplete physical and chemical characterization.
The committee did not follow that advice on the first two substances it considered. It voted to recommend BPC-157 — eight in favor, six against, one abstention — and also voted to recommend KPV. Members voting yes largely framed it as harm reduction: patients are already sourcing these peptides from the unregulated gray market, and supervised compounding is the safer of two imperfect options. Reporting on the session also noted that many yes votes came from committee members who represent or advise telehealth companies, an industry with a direct commercial stake in peptide access.
What “reclassification” does and does not mean
A February 2026 HHS announcement raised expectations that roughly 14 restricted peptides would return to Category 1. That expectation drove a lot of headlines, and the July committee vote moved two peptides closer to it — but as a matter of rule, nothing has changed. Three things are worth holding separately:
- A PCAC recommendation is non-binding. The FDA decides, and here that would mean reversing its own published position.
- Formal notice-and-comment rulemaking — which can take more than a year — is what actually changes the list.
- Category 1 is not FDA approval. It only permits compounding under interim policy. FDA approval requires clinical trials and a New Drug Application. Compounded medications are not FDA-approved finished products.
Practically: if a seller cites the July 2026 vote as evidence that BPC-157 is now legal to buy, that is running ahead of the rule.
What this means if you are considering peptides
The honest read: work with a licensed clinician and a legitimate pharmacy, and start with peptides that have a real legal pathway today — the sermorelin vs tesamorelin decision is where most people begin. Treat any provider offering restricted Category 2 peptides as a research-chemical route without clinical oversight as a warning sign, not a bargain — see compounded peptides vs research chemicals.
Compounded medications are prescribed and prepared by state-licensed, FDA-regulated compounding pharmacies. They are not FDA-approved finished products, and nothing here is a promise of results. Peptide use is decided within a licensed clinical relationship, and regulatory status changes — verify current FDA listings before acting.
Frequently asked questions
What peptides can I legally get prescribed in 2026? Tesamorelin (FDA-approved), plus sermorelin and ipamorelin (Category 1, compoundable under prescription while reviewed).
Is BPC-157 legal to prescribe? Not yet — it remains Category 2. The July 23, 2026 committee vote (8–6–1) recommended listing it, but that is non-binding and the FDA has not acted.
Didn’t the FDA make 14 peptides legal? That was expected after a Feb 2026 announcement but had not become a rule. The July meeting recommended BPC-157 and KPV — a step, not a final decision.
Category 1 vs Category 2? Category 1 may be compounded under prescription during review; Category 2 may not.
Does Category 1 mean safe and effective? No — it is an interim compounding status, not an FDA efficacy determination.
Sources
- FDA, “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee,” agenda and briefing documents (fda.gov), captured 2026-07-23.
- Contemporaneous reporting on the July 23, 2026 PCAC session — the 8–6–1 BPC-157 vote, the KPV vote, member rationale, and committee-member affiliations (STAT), captured 2026-07-23.
- FDA Law Blog, “FDA’s Pep(tide) Rally,” 2026-04 (thefdalawblog.com), on PCAC process and rulemaking timelines.
- OpenLoop Health, “What Peptides Are Becoming Legal in 2026?” and peptide FDA status trackers (openloophealth.com; newtropin.com), captured 2026-07-23.
- AgeMD, “BPC-157 FDA Status 2026” (agemd.com), captured 2026-07-23.